Presbyopia

Qlosi (Orasis Pharmaceuticals) approved to treat presbyopia.

Innovations in multifocal contact lenses have expanded options.

Post-hoc data helps shine light on better understanding what patient demographics are best suited for presbyopia drops.

The TOTAL30 multifocal contact lens helps address the needs of visual and comfort for patients with presbyopia.

Research presented at the American Academy of Optometry 2023 meeting illustrates success in fitting presbyopia patients in soft multifocal contact lenses.

Results of the BRIO-I study, the first of 2 phase 3 clinical trials of Brimochol PF, a topical, fixed-dose combination for the treatment of presbyopia, have recently been released.

Ben Bergo, CEO of Visus, shares data from the company's pivotal phase 3 BRIO-1 trial, as well as answers questions about Brimochol PF.

Making the most of multifocal contact lenses in your practice.

Doctors should consider a few key points before writing a prescription.

Managing patient expectations is key to selecting the best lens

Infuse Multifocal silicone hydrogel (SiHy) daily disposable contact lenses leverage Bausch + Lomb’s proprietary lens tech to deliver all-day comfort and seamless transitions between near, intermediate, and distance vision for patients with presbyopia.

Preeya Gupta, MD, reported results of the trials at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, showed that CSF-1, a low dose pilocarpine with an optimized formulation, demonstrated significant 2-line improvement from baseline.

Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia. The FDA has now approved a two-dose option.

A look back on what happened in optometry during the week of March 20-March 24.

Following the enrollment completion for Brimochol PF, topline Phase 3 data for the presbyopia candidate is expected in Q2 2023.

A look back on what's happened in optometry during the week of February 25-March 2.

Milton M. Hom, OD, FAAO, FACAAI (Sc), shares key takeaways from his SECO 2023 presentation, "Drugs of the future."

A look back on what's happened in optometry during the week of February 18-February 23.

A PDUFA goal date of October 22, 2023 was assigned to the investigational eye drop candidate for the treatment of presbyopia.

A look back on what's happened in optometry during the week of Jan. 7-Jan. 12, 2023.

The VEGA-2 pivotal trial is investigating Nyxol alone and Nyxol with adjunctive low-dose pilocarpine therapy for the treatment of presbyopia.

Panel discusses the highs and lows of treating patients with this condition.

Considering safety and efficacy of new drops and the potential impact on your patients.

Expert eye care specialists discuss the role of miotic agents in targeting presbyopia in patients.

Sean W. Smolenyak, OD, gives a brief overview of presbyopia, including the cause and available treatments.

Drs Andrew S. Morgenstern and Francis S. Mah provide insight on the functionality of ocular accommodation as an autofocus lens and how this is affected in patients with presbyopia.

Francis S. Mah, MD, and Andrew S. Morgenstern, OD, FAAO, FNAP, review the impact of presbyopia on quality of life as well as current treatment options and unmet needs for disease management.

Ocuphire seeks to develop and commercialize Nyxol for the reversal of mydriasis, presbyopia and night vision disturbances.

Erin Rueff, OD, PhD, FAAO, shares highlights from her 2022 American Academy of Optometry presentations in the contact lens space.

Presbyopia-correcting drops for patients with low, up-close visual function.